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Abstract
Therapeutics which reduce the pathology in sickle cell syndromes are needed, particularly non-
cytotoxic therapeutics. Fetal hemoglobin (HbF, α2γ2) is established as a major regulator of disease
severity; increased HbF levels correlate with milder clinical courses and improved survival.
Accordingly, sodium dimethylbutyrate (HQK-1001), an orally-bioavailable, promoter-targeted
fetal globin gene-inducing agent, was evaluated in a randomized, blinded, dose-ranging Phase I/II
trial in 24 adult patients with HbSS or S/β thalassemia, to determine safety and tolerability of three
escalating dose levels. The study therapeutic was administered once daily for two 6-week cycles,
with a 2-week interim dose holiday. Twenty-one patients completed the study. Five patients
received study drug at 10 or 20 mg/kg doses, seven patients received study drug at 30 mg/kg/dose,
and 4 patients received placebo. HQK-1001 was well-tolerated with no unexpected drug-related
adverse events; a dose-limiting toxicity was not identified. Plasma drug levels were sustained
above targeted levels for 24 hours. Increases in HbF above baseline were observed particularly
with 30 mg/kg/day doses; in five of seven treated patients, a mean absolute increase in HbF of 0.2
g/dl and a mean increase in total hemoglobin (Hgb) of 0.83 g/dl above baseline were observed,
whereas no increases occurred in placebo-treated controls. These findings of favorable PK
profiles, tolerability, early rises in HbF and total Hgb indicate that trials of longer duration appear
warranted to more definitively evaluate the therapeutic potential of HQK-1001 in sickle cell
disease.
INTRODUCTION
Sickle cell disease, characterized by HbS (α2βS2), is a genetic blood disorder which is
recognized by WHO as a global health burden.1 Sickle cell disease causes hemolytic
anemia, vaso-occlusion, and cell adhesion, producing widespread organ damage and early
mortality.2-3 Fetal globin, or HbF (α2γ2), has been established as the major modulator of
disease severity in biochemical, epidemiologic, and clinical trials.4-22 While HbF levels
>8.6% correlate with improved survival, levels >20% are associated with amelioration of
most complications.8-14,17-18,21-23 One therapeutic, hydroxyurea, is approved for treatment
of sickle cell disease and confers considerable benefit in some patients; reduced frequency
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of clinical events and improved survival in adult patients are associated with rises in
absolute HbF levels > 0.5 g/dl.17-18,20 Additional therapeutics that induce HbF expression
by different mechanisms are needed for many patients to achieve levels of HbF which are
disease-modifying.4,23
Previously, two other classes of therapeutics have produced high HbF levels in adult sickle
cell patients: demethylating agents (5-azacytidine and decitabine) and short chain fatty
acids, of which some are histone deacetylase inhibitors, such as arginine butyrate. 24-26
Clinical trials of these agents resulted in a mean 3-fold increase in HbF, to levels of 18-30%,
in adult patients with an associated rise in total hemoglobin of 1 gm/dl above baseline. 24-28
However, these agents require parenteral administration, while oral therapeutics are more
feasible and preferable for long-term use. Sodium 2,2 dimethylbutyrate (SDMB,
HQK-1001) is a short-chain fatty acid derivative which induces expression of the γ–globin
gene promoter in reporter gene assays, γ–globin mRNA and HbF in cultured erythroid
progenitors, and of HbF in anemic baboons.29-32 SDMB is orally bio-available with a half-
life of several hours in non-human primates and in normal human volunteers.30,33 A dose-
ranging trial to evaluate safety, tolerability, and pharmacokinetics in normal human
volunteers demonstrated no significant drug-related adverse events, and produced
pharmacokinetic profiles which are favorable for once-daily dosing, with a t1/2 of 9-11 hours
at doses projected to be required for therapeutic induction of fetal globin.33 Accordingly, a
blinded, sequential dose-escalating safety and tolerability study of sodium 2,2
dimethylbutyrate (HQK-1001) was performed in patients with sickle cell disease. The drug
was well-tolerated, and early signals of induced fetal globin expression were observed in
some subjects during this short-term drug administration.
MATERIALS AND METHODS
The primary objective of this trial (NCT00842088) was to determine the safety and
tolerability of HQK-1001 administered for 12 weeks at three dose levels in subjects with
sickle cell disease. Secondary objectives were to evaluate the pharmacokinetic (PK) profiles
of the drug with repeated doses, to assess potential pharmacodynamic effects on fetal globin
expression within the relatively brief dosing period, and to identify dose regimens and
schedules suitable for further evaluation in follow-on trials. The design was a randomized,
blinded, placebo-controlled, sequential dose-escalating trial and was conducted in seven
clinical sites, six in the United States and one in Jamaica, with approval of their
Investigational Review Boards. Eligibility criteria required that subjects have an established
diagnosis of Hb SS or sickle/β-thalassemia, were ages 12-60 years inclusive, and had a
history of an average of one significant sickle cell-related medical event requiring medical
attention per year for in the preceding three years, or at least one hospitalization for acute
chest syndrome in the previous five years. Concomitant hydroxyurea therapy was allowed, if
a stable dose was established in the subject for at least six months. A baseline screening HbF
level >2% was required, as this threshold was necessary for responses to arginine butyrate in
previous trials.26 Exclusion criteria included a red blood cell transfusion within 3 months
before beginning drug or participation in a regular transfusion program, acute vaso-
occlusive events within 3 weeks, a history of >4 hospitalizations for sickle cell related
events in the preceding 12 months, renal or hepatic compromise, or pulmonary hypertension
requiring oxygen therapy. Randomization to active treatment or placebo was assigned
according to a table generated by random numbers prepared by biostatisticians in an
independent contract research organization, Quintiles, Inc., which monitored the study.
The study drug was administered once-daily for 2 cycles of 6 weeks each. Because arginine
butyrate was more effective when administered in an intermittent or pulsed fashion, a 2-
week dose holiday was provided between the two treatment cycles.26 Initial doses were
Kutlar et al. Page 2













administered with observation in a clinical research unit. Cohorts of 10, 20, and 30 mg/kg/
doses included at least one placebo subject and six or seven active treatment subjects, and
dose escalation between cohorts was allowed sequentially after review of the first four
subjects’ courses by an independent Safety Monitoring Committee. Patients received
supplements with folic acid, 1 mg/day orally, and ferrous gluconate if their ferritin was
<1000ng/ml, to support erythropoiesis, as previously shown to be necessary for effective
HbF induction.34 Safety monitoring by blinded investigators included physical
examinations, laboratory studies of hematologic, renal, and hepatic function every two
weeks, periodic coagulation analyses, electrocardiograms, monthly pregnancy tests, and
adverse event monitoring every two weeks during the dosing period and for four weeks after
dosing was completed.
HbF was assayed by HPLC at a central reference laboratory by blinded personnel, and F-
cells, proportions of red blood cells containing HbF, was assessed by flow cytometry also by
blinded personnel. Samples were collected for PK profiles on day 6; drug levels were
assayed by previously established methods.33 Pharmacokinetic parameters which were
analyzed included area under the curve from time 0 to last quantifiable concentration
(AUC(0-lqc)), AUC from time 0 to infinity (AUC(0-∞)), maximum concentration of drug
(Cmax), minimum concentration of drug (Cmin), average concentration of drug (Cavg), time
of maximum concentration (Tmax), elimination half-life (T1/2), total body clearance (CL/F),
and elimination rate constant (λz). Pharmacokinetic analyses were performed using
WinNonLinR Professional version 5.2 (Parsight Corp., Mountain View, CA.), as previously
described.33 Descriptive statistics were prepared and statistical analyses were performed by
J.M. White Inc., using Statistical Analysis Software (SAS) version 9 or higher. Adverse
events were characterized by dose level or placebo using MedDRA version 9 preferred term
coding, and laboratory abnormality severity was graded using NCI CTC version 3. All 24
subjects who enrolled received at least one dose of the study drug, and all were included in
the safety analysis. The blinded principle investigator (PI) at each site determined adverse
event (AE) relationship to study drug.
RESULTS
Thirty patients were screened for eligibility criteria; twenty-four subjects met the required
criteria, signed informed consent, and were enrolled. Demographic characteristics and
baseline hematologic features of the study participants are shown in Table I. Patients ranged
in age from 14 to 57 years; the mean ratio of males to females was 0.6 in the four cohorts.
The subjects’ genotypes were homozygous Hb SS except for one patient who had HbS-β+
thalassemia. No apparent differences in demographic characteristics of age, ethnicity, or
baseline height and weight were observed across treatment groups. The patients were of
Jamaican or African American ethnicity. All subjects had significant past medical histories
characteristic of sickle cell disease, including vaso-occlusive crises, osteonecrosis,
pulmonary hypertension, cholelithiasis, priapism, proliferative retinopathy, and joint
replacement for avascular necrosis. Twelve subjects had concomitant hydroxyurea (HU)
use, including 75% of placebo subjects, and in 57, 50, and 29% of the 10, 20, and 30 mg/kg
dose cohorts, respectively. Baseline median HbF levels were 14.5, 7.7, 11.2, and 10.8% in
the placebo-treated, 10, 20, and 30 mg/kg dose cohorts, respectively. Mean baseline HbF
was in those subjects receiving treatment with HU was 14.4% and in subjects not receiving
HU was 7.6%. Baseline total hemoglobin (Hgb) levels ranged from 5.9 to 11.8 g/dl; the
means at baseline were 8.8, 8.4, and 9.7 g/dl in the 10, 20, and 30 mg/kg dose 1001-treated
cohorts respectively and 9.3 g/dl in the placebo treated group. Baseline total Hb and % HbF
in individual subjects by assigned treatment or placebo group and HU use are shown in
Table Ib.
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Twenty-one patients completed the study and are included in the pharmacodynamic data
analysis, all patients were included in the safety analysis, and the drug was well-tolerated.
Reasons for early termination included development of more severe anemia (in association
with a port infection) which required transfusion within one week after starting the study,
and two study discontinuations unrelated to the study drug (inability to continue clinic visits
due to work obligations in one subject and hypersensitivity to a concomitant medication in
another). There were no unexpected, drug-related serious adverse events (SAEs). However,
nine subjects experienced 19 SAEs, summarized in Table 2A. These included 6 subjects
receiving active treatment who had 13 SAEs, and 3 placebo-treated subjects who had 6
SAEs. All the SAEs were considered to be expected sickle-related events, including vaso-
occlusive crises, an indwelling port infection, worsening anemia (associated with the port
infection), arthralgia, and extremity pain. One vaso-occlusive crisis in a placebo-treated
subject was classified as possibly drug-related by the blinded investigators. No differences
were detected in rates or severity of adverse events between patients who were or were not
receiving concomitant HU. Adverse events which were graded as mild to moderate and
reported in at least 10% of the subjects are shown in Table 2B; the most common events
included vomiting, abdominal pain, arthralgia, bone pain. Other adverse events considered
to be treatment-related included nausea and rash in two subjects. Minor transient laboratory
abnormalities in liver function tests occurred in four subjects; increases in transaminases
were graded as mild (Grade 1) or moderate (grade 2), and all returned to normal before the
end of the dosing period. The highest elevation in ALT was 256 (range 68-256) and in AST
was 169 U/L (range 73-169). Mild leukopenia occurred in one patient, in whom a decline in
WBC from 4.4 to 3.1 × 109/L occurred transiently, with subsequent increase to 5.6 × 109/L
without any change in study drug. There were no episodes of neutropenia or
thrombocytopenia. No dose-dependent pattern was observed for incidence and severity of
AEs, and there was no clear difference in the incidence and severity of AEs between the
HQK-1001 groups compared to placebo treated subjects, or to HU use, in this small, dose-
ranging study. Arthralgia was reported more frequently in the 30 mg/kg group, while bone
pain, cough, and headache were more often reported in the 20 mg/kg group, and pain in an
extremity was seen more frequently in the 10 mg/kg group.
Pharmacokinetic studies demonstrated mean PK profiles with dose-dependent increases in
AUC and Cmax of HQK-1001 (Figure 1), with plasma concentrations sustained for >10
hours above concentrations (12 to 71 μg/mL) which induce HbF in erythroid progenitors in
vitro.29 Mean maximum concentration increased as dose increased, ranging from 54.9 to
114.0 μg/mL over the 10 to 30 mg/kg dose range. The mean Tmax ranged from 2.0 to 2.4
hours. Mean minimum concentration at 24 hours was 15.5 μg/mL at 10 mg/kg, 17.8 μg/mL
at 20 mg/kg, and 17.6 μg/mL at 30 mg/kg, which are HbF-inducing “therapeutic” levels in
erythroid progenitors in vitro. The mean AUCinf ranged from 722 at 10 mg/kg to 1302 h*μg/
mL at 30 mg/kg. Mean CL/F values increased from 0.015 at 10 mg/kg to 0.026 L/h/kg at 30
mg/kg. However, the mean terminal phase half-life for HQK-1001 decreased from 13.8 at
10 mg/kg to 8.4 hours at 30 mg/kg. The decrease in exposure with increase in dose could
possibly be due to an increase in the intrinsic clearance. These studies confirm that this
agent has more favorable PK profiles compared to prior-generation butyrates, which are
rapidly metabolized and required significantly higher doses administered by infusions or
multiple doses, three times/day, such as arginine butyrate and phenylbutyrate.26,35
Increases in median percent HbF, absolute HbF, and total hemoglobin on the last
observation at Day 97 were observed in at least half of the subjects in the 20 and 30 mg/kg
dose cohorts, while no increases were detected in the placebo group. Increases in % HbF of
> 1.1% above subjects’ baseline (which are reliably detected in the testing laboratory) were
observed at the end of the treatment period in 2/5 subjects treated with 10 mg/kg/dose (by
2.6 and 3.1% above baseline), in 3/5 patients treated at 20 mg/kg doses (by 1.6 to 3% above
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baseline), and in 5/7 patients treated with 30 mg/kg doses, (by 1.1 to 3.7% above baseline).
Individual responses are shown in Figure 2A. Absolute HbF also increased in the 30 mg/kg
dose cohort in five of seven treated subjects; the median increase was 1.82 g/dl, compared to
no increase in the 4 placebo-treated subjects. The per cent of F-cells increased from baseline
to day 97 by a median of 4.7 %, 0.45%, and 6.1% in the 10,20,and 30 mg/kg 1001 dose
cohorts respectively; in the placebo group, F-cells declined by −0.6%. A mean increase in
total Hgb of 0.83 g/dl above averaged baseline levels was observed in the 30 mg/kg dose
cohort (Figure 2B). Increases in HbF occurred in subjects both with and without
concomitant hydroxyurea therapy.
DISCUSSION
Sickle cell disease, a WHO-designated global health burden, still causes significant pain and
disability in many patients, despite the beneficial effects of hydroxyurea in approximately
half of treated adult patients, and higher responses in most children.15-21 Elevation of fetal
hemoglobin in sickle cell disease is well-established as a modulator of disease severity in
sickle cell disease, and agents which can be used without added toxicities with hydroxyurea
are needed for many patients.4,12,23 Sodium dimethylbutyrate, an orally bioavailable, short
chain fatty acid derivative fetal globin gene inducer was well-tolerated in this Phase I/II trial.
Pharmacokinetic studies demonstrated profiles suitable for once daily dosing, which is
preferable over multiple daily dosing in a treatment requiring long-term use.
Dose-limiting toxicity was not identified at the dose levels studied here. HU trials typically
demonstrate increases in HbF after 6 months of treatment, and HbF responses in adult
patients in the MSH trial averaged 3.5% above baseline.19 Achieving HbF levels > 0.5 g/dl
is associated with increased survival in long (9 and 17 year) follow-up studies of HU in
adult sickle cell patients.17-18
This dose-ranging safety trial was not designed, dosed for an adequate duration of time, or
powered to detect changes in HbF. However, some increases in HbF were detected in
subjects treated with the study drug and the findings suggest a trend of increasing response
rates and a higher magnitude of effect on HbF and total Hb as the dose was increased. The
early signals in HbF observed in this safety study, particularly at the 30 mg/kg/dose level,
are therefore encouraging, and also suggest that higher HbF levels may be inducible with
longer duration of administration.
Sickle cell disease is characterized by anemia related to short red cell lifespan, intravascular
hemolysis, and inappropriately low levels of erythropoietin for the degree of anemia.2-3,11,35
The anemia typically becomes more severe with increasing age, perhaps related to renal
compromise and reduced erythropoietin levels. This HbF-inducing therapeutic candidate,
HQK-1001, was selected for clinical development for its improved PK profile in non-human
primates compared to prior generation butyrates, and a second activity of increasing
erythroid cell proliferation through STAT-5 signaling and enhanced Bcl-xL expression, in
vitro and in vivo, in anemic baboons.29-31 Demonstration of any erythropoietic effect was
not expected over the brief time-frame of this study in sickle cell disease, in the presence of
markedly reduced red blood cell lifespan of 16 days, so it is encouraging that increases in
total hemoglobin (mean rise of 0.8 g/dl) occurred in the 30 mg/kg dose cohort. It is also
interesting that changes in total Hgb were observed to a lesser extent in subjects receiving
concomitant hydroxyurea treatment, as a proliferative effect would be expected to be
inhibited by the cytostatic effects of hydroxyurea.
Steinberg and others have strongly recommended that a combination therapeutic approach is
needed to modify clinical disease in many patients with sickle cell disease, as multiple
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agents acting by different mechanisms are usually required for effective control of most
systemic medical conditions, and differences in drug metabolism often render response rates
to any drug 25-40% at best.10,23,35,38
Previous studies by Franco and colleagues documented that red cells which express HbF (F-
cells), whether naturally-occurring or associated with a pharmacologic treatment, undergo
selective survival and become enriched by 2-to 3-fold in sickle cell disease, resulting in a
progressive increase in total HbF levels over time.10 These findings would predict that
longer administration of HQK-1001 should result in higher levels of HbF than observed in
this relatively brief trial in small cohorts.
The complex pathophysiology of sickle cell disease has been increasingly well-
characterized, with multiple therapeutic targets identified, yet only one therapeutic to reduce
the underlying pathology has been approved in over a decade. Stem cell transplant, the one
curative approach, is available for a minority of patients for whom appropriate donors are
found.37 Despite documented benefit from HbF induction >0.5 g/dl with hydroxyurea, many
adults still suffer chronic morbidity, and there is still an early mortality rate > 40%.17-18
Several prior generation short chain fatty acids have HbF-inducing activity, and are
appealing for their targeted effects in displacing repressor complexes, including BCL-11A
and HDAC-3, and recruiting EKLF, but their feasibility for chronic use is problematic due
to pharmacokinetic challenges.28,32,38-9 These early clinical findings now with sodium 2,2
dimethylbutyrate, in combination with prior studies in molecular, cellular, and nonhuman
primate models, strongly suggest that HQK-1001 offers potential for increasing HbF in
sickle cell disease without cytotoxicity, and its pharmacokinetic profile is feasible for long-
term administration. Basal HbF levels vary widely in association with diverse genetic
modifier profiles, which are likely to influence responses to HbF-inducing therapeutics. 40-48
It is therefore encouraging that five of seven subjects who received the highest dose level
had a detectable rise in HbF above baseline in the presence of quite different basal HbF
levels in this brief time-frame. Further trials with longer administration of HQK-1001 in
larger numbers of sickle cell subjects appear warranted to more definitively evaluate its
therapeutic potential.
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Mean plasma levels of HQK-1001 on day 6 are shown by dose cohort.
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Changes from baseline in % HbF (top panel) and total Hgb (bottom panel) in the 3 dose
cohorts.
A. Changes in % HbF are shown in individual subjects in each of the 4 treatment groups.
Open symbols represent values in subjects on concomitant hydroxyurea treatment.
B. Changes from baseline in total Hgb are shown in individual subjects in each of the 4
treatment groups. Open symbols represent values in subjects on concomitant hydroxyurea
treatment.
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Table IA
Basic characteristics
Characteristics HQK-1001 (n=20) Placebo
(n = 4)
Male Gender 11 (60 %) 3 (75%)
Age in years, median
(Range) 29 (13-56) 34 (20-48)
Subjects taking Hydroxyurea 9 (45 %) 3 (75 %)
Weight in kg, median (Range) 63 (53 – 94) 59 (54 – 74)
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Table IB
Baseline total hemoglobin and % HbF in individual subjects. Hydroxyurea treatment
status is designated in the far right column
ID Group Hb (g/dL) HbF (%) HU
90301 Placebo 10.0 3.0 Yes
90803 Placebo 8.7 18.3 Yes
91101 Placebo 7.4 2.5
91103 Placebo 9.9 10.8 Yes
90101 10 mg/kg 9.2 7.7 Yes
90102 10 mg/kg 8.8 5.8 Yes
90103 10 mg/kg 11.9 14.7 Yes
90202 10 mg/kg 9.3 8.4
90203 10 mg/kg 8.0 2.9
91102 10 mg/kg 6.1 1.7
91104 10 mg/kg 5.9 12.2 Yes
90105 20 mg/kg 9.5 32.8 Yes
90204 20 mg/kg 8.5 8.3
90205 20 mg/kg 9.2 7.0
90801 20 mg/kg 11.8 10.2 Yes
90802 20 mg/kg 9.9 28.2 Yes
90901 20 mg/kg 11.4 12.2
90106 30 mg/kg 10.3 13.0
90206 30 mg/kg 6.3 6.4
90804 30 mg/kg 9.5 19.8 Yes
90805 30 mg/kg 8.4 2.9
90806 30 mg/kg 10.2 8.7 Yes
90902 30 mg/kg 7.5 3.7
91301 30 mg/kg 7.6 22.2
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Table IC
Baseline total hemoglobin and % HbF in individual subjects. Hydroxyurea treatment
status is designated in the far right column
ID Group Hb (g/dL) HbF (%) HU
90301 Placebo 10.0 3.0 Yes
90803 Placebo 8.7 18.3 Yes
91101 Placebo 7.4 2.5
91103 Placebo 9.9 10.8 Yes
90101 10 mg/kg 9.2 7.7 Yes
90102 10 mg/kg 8.8 5.8 Yes
90103 10 mg/kg 11.9 14.7 Yes
90202 10 mg/kg 9.3 8.4
90203 10 mg/kg 8.0 2.9
91102 10 mg/kg 6.1 1.7
91104 10 mg/kg 5.9 12.2 Yes
90105 20 mg/kg 9.5 32.8 Yes
90204 20 mg/kg 8.5 8.3
90205 20 mg/kg 9.2 7.0
90801 20 mg/kg 11.8 10.2 Yes
90802 20 mg/kg 9.9 28.2 Yes
90901 20 mg/kg 11.4 12.2
90106 30 mg/kg 10.3 13.0
90206 30 mg/kg 6.3 6.4
90804 30 mg/kg 9.5 19.8 Yes
90805 30 mg/kg 8.4 2.9
90806 30 mg/kg 10.2 8.7 Yes
90902 30 mg/kg 7.5 3.7
91301 30 mg/kg 7.6 22.2
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Table IIA
Adverse events listed as serious
Serious Adverse Events
SAE Terms HQK-1001 (n=20)N (%)
Placebo (n=4)
N (%)
Crisis 5 (25) 3 (75)
Anemia 1 (5) 0
Catheter site infection 1 (5) 0
Arthralgia 1 (5) 0
Pain in extremity 1 (5) 0
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Table IIB
Most common adverse events, occurring in 10% or more of subjects
Event
HQK-1001





Sickle cell crisis 45 75
Nausea 30 25




Chest Pain 15 25
URI 15 25
Back Pain 15 25
Vomiting 15 0
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